These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 20816696

  • 1. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A.
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [Abstract] [Full Text] [Related]

  • 2. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A.
    Biopolymers; 2004 Dec; 76(4):334-43. PubMed ID: 15386266
    [Abstract] [Full Text] [Related]

  • 3. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
    Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A.
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
    [Abstract] [Full Text] [Related]

  • 4. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
    Iaria ML, Fiorentini S, Focà E, Zicari S, Giagulli C, Caccuri F, Francisci D, Di Perri G, Castelli F, Baldelli F, Caruso A.
    Vaccine; 2014 Feb 19; 32(9):1072-8. PubMed ID: 24456624
    [Abstract] [Full Text] [Related]

  • 5. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM.
    AIDS; 1993 Oct 19; 7(10):1315-23. PubMed ID: 8267904
    [Abstract] [Full Text] [Related]

  • 6. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
    Fiorentini S, Marsico S, Becker PD, Iaria ML, Bruno R, Guzmán CA, Caruso A.
    Vaccine; 2008 Aug 26; 26(36):4758-65. PubMed ID: 18602957
    [Abstract] [Full Text] [Related]

  • 7. Functions of the HIV-1 matrix protein p17.
    Fiorentini S, Marini E, Caracciolo S, Caruso A.
    New Microbiol; 2006 Jan 26; 29(1):1-10. PubMed ID: 16608119
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D, Bolesta E, Naito T, Gzyl J, Kaneko Y, Kozbor D.
    J Hum Virol; 2001 Jan 26; 4(6):306-16. PubMed ID: 12082397
    [Abstract] [Full Text] [Related]

  • 9. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
    de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, Rimmelzwaan GF.
    Vaccine; 2009 Sep 25; 27(42):5735-9. PubMed ID: 19647812
    [Abstract] [Full Text] [Related]

  • 10. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 25; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 11. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
    Broliden PA, Morfeldt-Månsson L, Rosen J, Jondal M, Wahren B.
    Clin Exp Immunol; 1989 May 25; 76(2):216-21. PubMed ID: 2503275
    [Abstract] [Full Text] [Related]

  • 12. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
    Kageyama S, Katsumoto T, Taniguchi K, Ismail SI, Shimmen T, Sasao F, Gao M, Owatari S, Wakamiya N, Tsuchie H, Ueda S, Shiraki K, Kurimura T.
    Acta Virol; 1996 Sep 25; 40(4):195-200. PubMed ID: 9014009
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection.
    Mehta SU, Rupprecht KR, Hunt JC, Kramer DE, McRae BJ, Allen RG, Dawson GJ, Devare SG.
    AIDS Res Hum Retroviruses; 1990 Apr 25; 6(4):443-54. PubMed ID: 1692727
    [Abstract] [Full Text] [Related]

  • 14. [Anti-HIV-1 p17 antibody as anti-HIV agent].
    Tsuchie H, Tochikura A, Kageyama S, Kurimura T.
    Nihon Rinsho; 1993 Sep 25; 51 Suppl():213-8. PubMed ID: 8271386
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
    Tewari D, Notkins AL, Zhou P.
    J Gene Med; 2003 Mar 25; 5(3):182-9. PubMed ID: 12666184
    [Abstract] [Full Text] [Related]

  • 16. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
    Lottersberger J, Salvetti JL, Beltramini LM, Tonarelli G.
    Rev Argent Microbiol; 2004 Mar 25; 36(4):151-7. PubMed ID: 15786866
    [Abstract] [Full Text] [Related]

  • 17. Vaccine-induced HIV seropositivity: a problem on the rise.
    Van Braeckel E, Koutsoukos M, Bourguignon P, Clement F, McNally L, Leroux-Roels G.
    J Clin Virol; 2011 Apr 25; 50(4):334-7. PubMed ID: 21300566
    [Abstract] [Full Text] [Related]

  • 18. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K, Boykins RA, Hewlett IK, Wood OL, Clouse KA, Yamada KM, Dhawan S.
    Peptides; 2007 Mar 25; 28(3):496-504. PubMed ID: 17188401
    [Abstract] [Full Text] [Related]

  • 19. Pairwise decomposition of residue interaction energies of single chain Fv with HIV-1 p17 epitope variants.
    Lee VS, Tue-ngeun P, Nangola S, Kitidee K, Jitonnom J, Nimmanpipug P, Jiranusornkul S, Tayapiwatana C.
    Mol Immunol; 2010 Feb 25; 47(5):982-90. PubMed ID: 20022377
    [Abstract] [Full Text] [Related]

  • 20. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.
    Wagner R, Deml L, Schirmbeck R, Reimann J, Wolf H.
    Behring Inst Mitt; 1994 Dec 25; (95):23-34. PubMed ID: 7755506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.